LMX 4% OTC
Generic Name and Formulations:
Lidocaine 4%; crm.
Ferndale Laboratories, Inc.
Indications for LMX 4%:
Topical anesthetic for minor wounds, burns, abrasions, insect bites, or pretreatment before injections, minor procedures.
Adults and Children:
Use occlusive dressing for young children or if cream may be disturbed. Clean area with mild soap; do not use alcohol or acetone. <2yrs: individualize. ≥2yrs: massage small amount of cream into skin, then completely cover affected area; leave on for 30–60 minutes (may add more cream); remove.
Not for use near tympanic membrane or on broken skin. Avoid eyes, mucous membranes, ingestion (esp. children or pets), application to large areas, and using for longer than recommended time. Pregnancy. Nursing mothers.
Irritation, pruritus, erythema, rash, systemic effects.
Crm 5g—1, 5
Crm 5g—1 (w. 2 dressings)
Crm 5g—5 (w. 10 dressings)
Crm 15g, 30g—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline